Ardsley Advisory Partners’s ProQR Therapeutics PRQR Stock Holding History

Ardsley Advisory Partners’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-20,000	Closed	-$198K	–	149
2019 Q4	$198K	Buy	+20,000	New	+$156K	0.03%	130
2018 Q4	–	Sell	-25,000	Closed	-$484K	–	141
2018 Q3	$484K	Sell	25,000 -25,000	-50%	-$266K	0.07%	107
2018 Q2	$365K	Buy	+50,000	New	+$252K	0.05%	124

Other funds holding PRQR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ardsley Advisory Partners's PRQR Position: Q1 2020 in Review

Ardsley Advisory Partners sold out of ProQR Therapeutics (PRQR) in Q1 2020, closing a stake of 20,000 shares — an estimated $198K sold.

Ardsley Advisory Partners first reported a position in PRQR in Q2 2018 and held it in 3 quarters. The position peaked at $484K in Q3 2018. 44 funds tracked by Wall St. Rank hold PRQR as of Q1 2020.

Ardsley Advisory Partners reported no remaining ProQR Therapeutics position as of Q1 2020 after selling out during the quarter.
Ardsley Advisory Partners sold 20,000 ProQR Therapeutics shares in Q1 2020, an estimated $198K.
Ardsley Advisory Partners first reported a position in ProQR Therapeutics in Q2 2018 and held it in 3 quarters.
Ardsley Advisory Partners's ProQR Therapeutics position peaked at $484K in Q3 2018.
44 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2020.

Based on Ardsley Advisory Partners's 13F filing for Q1 2020, filed 15 May 2020.